GlaxoSmithKline Launches Chinese R&D Centre with Appointment of
Head in Shanghai
Jingwu Zang to lead work on neurogenerative diseases
LONDON, May 24, 2007-GlaxoSmithKline (GSK) today announces the
appointment of Jingwu Zang to head a new GSK research and
development centre in Shanghai, China. His appointment, as Senior
Vice President, will be effective in June.
GSK R&D China will focus on research into
neurodegeneration with the objective of creating new medicines for
such severe disorders as multiple sclerosis, Parkinson’s
disease, and Alzheimer’s disease. The centre will eventually
direct the global discovery and development activities within its
therapeutic area, from drug-target identification to late-stage
clinical studies, while collaborating with research institutions
elsewhere in China and other countries.
Dr. Zang, a neurologist and researcher in immunological and
neurodegenerative disorders, will lead the scientific activities of
the centre and the hiring of staff, which will begin immediately.
It is anticipated that over the next decade GSK R&D China will
grow to become one of the larger R&D facilities within GSK. Dr.
Zang will report directly to Moncef Slaoui, Chairman, GSK R&D.
Dr. Slaoui commented: “We are entering an exciting
period of expansion for our R&D organization as it builds on
the strength of the superb science now being conducted in China. We
intend to be part of a future in which the phrase ‘discovered
in China’ is heard as often as ‘made in China’ is
“Our initiative in China reflects our commitment to ally
GSK with talented researchers wherever we can find them and to
further encourage within R&D the contest of ideas needed to
create new medicines. It shows as well our commitment to the
neurosciences, where many of the greatest challenges in drug
discovery and development are to be found. Indeed, as we create a
centre in Chinato focus on neurodegenerative disorders, we will
re-focus our largely UK-based neurology drug-discovery efforts on
finding new therapies for pain, epilepsy, and brain injury.”
Until his appointment at GSK, Dr. Zang served most recently as
the founding director and a professor at the Instituteof Health
Science sin Shanghai. The Institute is an affiliate of the Chinese
Academy of Sciences and the Shanghai Jiao Tong University School of
Medicine. Under Dr. Zang’s direction, the Institute grew to
comprise a staff of 150 and a cadre of graduate students numbering
about 250 while broadening its mission to bridge the basic sciences
and translational medicine.
Dr. Zang also served as research director of the Baylor
Multiple Sclerosis Centre, Houston, Texas, where he concentrated on
clinical research in multiple sclerosis and neuroimmunology.
Dr. Zang earned an M.D. degree at the Shanghai Second Medical
University(now Shanghai Jiao Tong) and a Ph.D. degree in immunology
at the University of Brussels, where he started his research into
multiple sclerosis. He went on to complete postdoctoral training at
Harvard Medical School and a clinical residency at Baylor College
of Medicine. Dr. Zang has been Professor of Neurology at Baylor and
held positions at the Chinese Academy of Sciences and Shanghai Jiao
Tong. He is licensed in both Texas and Shanghai and has more than
20 years of experience in translational research. He is an author
on more than 100 scientific papers, review articles, and book
“Dr. Zang brings to his role at GSK both an
understanding of the biomedical research community in China and
international experience as a scientist and clinician,” said
Dr. Slaoui. “He has, moreover, demonstrated his capacity to
assemble the talent required to make a success of a new R&D
GlaxoSmithKline in China
The heritage of GlaxoSmithKline in China dates from 1908. GSK
has its Chinese headquarters in Shanghai and major offices in
Beijing, Tianjin, and Hong Kong. The company employs more than
2,200 people in China, and pursues all its businesses there:
prescription medicines, vaccines, and over-the-counter medicines.
It has manufacturing plants in Shanghai, Tianjin and Suzhou.
GSK also has a growing R&D presence in China. For the past
decade, GSK has collaborated in discovery with the combinatorial
Chemistry Laboratory at the Shanghai Institute of Materia Medica,
the drug research institute of the Chinese Academy of Sciences. In
development, GSK started 17 clinical studies in China during 2006
and plans an additional 18 in 2007.
GlaxoSmithKline is one of the world’s leading
research-based pharmaceutical and healthcare companies.
GlaxoSmithKline is committed to improving the quality of human life
by enabling people to do more, feel better and live longer. For
company information visit www.gsk.com.
UK Media enquiries:
(020) 8047 5502
(020) 8047 5502
(020) 8047 5502
US Media enquiries:
(215) 751 7709
(215) 751 7709
Mary Anne Rhyne
(919) 483 2839
European Analyst/Investor enquiries:
(020) 8047 5542
(020) 8047 5564
(020) 8047 5543
US Analyst/ Investor enquiries:
Posted: May 2007